Vaxart (NASDAQ:VXRT - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.05, Zacks reports. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%. The business had revenue of $15.19 million during the quarter, compared to analyst estimates of $15.68 million.
Vaxart Stock Performance
Shares of NASDAQ:VXRT traded down $0.00 during midday trading on Monday, reaching $0.51. 1,497,135 shares of the company's stock were exchanged, compared to its average volume of 2,375,633. The firm has a market capitalization of $116.61 million, a PE ratio of -1.25 and a beta of 1.69. The company's 50 day simple moving average is $0.65 and its two-hundred day simple moving average is $0.71. Vaxart has a 12 month low of $0.45 and a 12 month high of $1.41.
Vaxart Company Profile
(
Get Free Report)
Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
Further Reading
Before you consider Vaxart, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxart wasn't on the list.
While Vaxart currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
